Please assess the completion status of the following clinical trial:

Trial Title: Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is between the ages of 16 - 60 years old~* A clinical diagnosis of Type 1 Diabetes Mellitus, as determined by the Investigator, for a minimum of 12 months duration~* Subject has been on a Medtronic insulin pump for at least 3 months, which includes but is not limited to those on sensor augmented insulin pump therapy~* Subject has an A1C value between ≥ 7.0% and ≤ 10.0% at time of enrollment; as measured during the screening visit~* Subject must have a documented stress treadmill test within the last three years of enrollment if the subject had diabetes for \>20 years~* Subject willing to follow protocol and procedures for study.~Exclusion Criteria:~* Systolic blood pressure on screening visit is \>140 Millimeters of Mercury~* Diastolic blood pressure on screening visit is \>90 Millimeters of Mercury~* Subject has a history of hypoglycemic seizure or hypoglycemic coma within the last two years~* Subject unable to tolerate tape adhesive in the area of sensor placement;~* Subject has any active adverse skin condition in the area of sensor placement (i.e. psoriasis, rash, staphylococcus infection) that is not resolved at the time of enrollment~* Subject is pregnant or plans to become pregnant during the course of the study~* Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease~* Subject has active Graves disease~* Subject with renal impairment or creatinine above the normal reference range (of the laboratory that the clinical site is utilizing), as demonstrated by the screening laboratory value~* Subject is outside of the normal reference range (of the laboratory that the clinical site is utilizing) for hematocrit, as demonstrated by screening laboratory value~* Subject is outside of the normal reference range (of the laboratory that the clinical site is utilizing) for potassium, as demonstrated by screening laboratory value~* Subject is outside of the normal reference range (of the laboratory that the clinical site is utilizing) for Thyroid-Stimulating Hormone (TSH), as demonstrated by screening laboratory value~* Subject is outside of the normal reference range (of the laboratory that the clinical site is utilizing) for free Thyroxine (T4), as demonstrated by screening laboratory value~* Subject has history of smoking for \>5 years~* Electrocardiogram findings observed during the screening visit, which are deemed by the investigator to represent active ischemia or a condition that would compromise subject safety~* The stress treadmill (if subject met inclusion criteria #7) results are deemed by the investigator to represent active ischemia or a condition that would compromise subject safety~* Subject is currently participating in an investigational study (drug or device)~* Subject is currently on beta blocker medication~* Subject has taken oral or injectable steroids within the last 30 days~* Subject is deemed by the Investigator to be unwilling or unable to follow the protocol~* Subject has a history of diagnosed medical eating disorder~* Subject has a history of known illicit drug abuse~* Subject has a history of known abuse with prescription medication~* Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely per investigator discretion~* Subject has a history of current alcohol abuse~* Any other condition including abnormalities found on the screening tests which in the opinion of the Investigator, may preclude him/her from participating in the study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: OTHER): Group A will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature activated
- Group B (Type: OTHER): Group B will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature deactivated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete